Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 33-36, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-285930
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC).</p><p><b>METHODS</b>The clinical data of 10 patients with unresectable HCC treated by sorafenib combined with TACE in the Department of Radiology, the First Hospital of China Medical University were retrospectively analyzed. The efficacy was evaluated according to the modified Response Evaluation Criteria in Solid Tumors assessment. Survival was analyzed by Kaplan-Meier method. Safety was evaluated according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0.</p><p><b>RESULTS</b>Among the 10 patients, 2 achieved complete response, 3 achieved partial response, 3 achieved stable disease, and 2 experienced progressive disease. The median overall survival of the cohort was 29.5 months. Different degree of adverse drug reactions (ADRs) occurred in 9 patients but all were at grade 3 or lower. The most common ADRs were hand-foot skin reaction (7/10) and diarrhea (6/10).</p><p><b>CONCLUSION</b>The combination of sorafenib and TACE is an effective and safe treatment for HCC.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Compuestos de Fenilurea
/
Terapéutica
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Quimioembolización Terapéutica
/
Niacinamida
/
Carcinoma Hepatocelular
/
Usos Terapéuticos
/
Neoplasias Hepáticas
/
Antineoplásicos
Tipo de estudio:
Estudio observacional
Límite:
Adulto
/
Anciano
/
Aged80
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Acta Academiae Medicinae Sinicae
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS